1.. Introduction
================

Extensive epidemiological studies have demonstrated that environmental exposure to arsenic causes cancer of the skin, lung, and bladder \[[@b1-ijerph-08-02090]--[@b3-ijerph-08-02090]\] and is also a co-carcinogen in combination with UV light for skin cancer \[[@b4-ijerph-08-02090]\]. In addition, exposure to arsenic either chronically through the drinking water \[[@b5-ijerph-08-02090]\] or acutely through medical therapy for acute promyelocytic leukemia or poisoning \[[@b6-ijerph-08-02090],[@b7-ijerph-08-02090]\] is associated with cardiovascular abnormalities \[[@b8-ijerph-08-02090],[@b9-ijerph-08-02090]\]. This is frequently manifest as a prolongation of the QT (time between initial deflection of QRS complex to the end of T wave) interval as measured on an electrocardiogram, resulting in life-threatening malignant ventricular arrhythmias \[[@b7-ijerph-08-02090]\].

Mechanistic studies indicate that arsenic enhances inflammation of vascular tissues, activates oxidative signaling, disrupts lipid metabolism, and increases lipid oxidation \[[@b8-ijerph-08-02090]\]. These effects can produce endothelial cell dysfunction directly to the vascular cells and indirectly through the liver. In addition, the epigenetic changes induced by arsenic in the liver appear to produce a chronic state of stress and inflammation, resulting in not only liver disease but also systemic vascular disease \[[@b8-ijerph-08-02090]\]. In particular, arsenic exposure increases the risk of prolonged QT interval duration, which is associated with atherosclerosis \[[@b10-ijerph-08-02090],[@b11-ijerph-08-02090]\]. No studies have implicated a role for arsenic on cardiomyocytes *per se*; however, to our knowledge, no *in vitro* exposures of such cells to arsenic have been performed.

To understand these diverse effects of arsenic, toxicogenomic analyses involving cDNA microarray have been used to identify alterations in global gene expression and pathways in cells exposed to arsenic *in vitro* as well as in animals and humans exposed to arsenic \[[@b12-ijerph-08-02090]--[@b16-ijerph-08-02090]\]. The aberrantly expressed genes identified in these studies include those coding for heat shock proteins, DNA damage response, antioxidant activity, inflammation signaling, cell-cycle regulation, and apoptosis \[[@b16-ijerph-08-02090]\].

Although global gene expression studies have provided considerable insights into the toxicity pathways affected by arsenic, real-time PCR (RT-PCR) has been used to confirm the arsenic-associated altered gene expression of only a few genes in these studies. The development of a novel qRT-PCR-based technique called Taqman Low-Density Array (TLDA) allows for the simultaneous testing of 48 or 96 genes in a micro-fluidic card format in which the user can specify the genes to be analyzed \[[@b17-ijerph-08-02090]\]. This technology has been shown to be a sensitive and reproducible system for analyzing gene expression \[[@b18-ijerph-08-02090]\], and it could be of value in confirming the ability of arsenic to alter the expression of genes identified initially by cDNA microarray.

To explore this possibility, and especially to assess some of the toxicogenomic effects of arsenic associated with cardiovascular abnormalities, we used a TLDA to evaluate gene expression in 48 genes in RNA isolated from (a) blood of 159 subjects exposed chronically to arsenic as well as (b) human cardiomyocytes exposed *in vitro* to arsenic. The 48 genes ([Table 1](#t1-ijerph-08-02090){ref-type="table"}) were selected based on the previous cDNA microarray studies described above and fell into 10 functional groups: endogenous control, Nrf2 pathway, heat shock protein, apoptosis, inflammation, NF-κB pathway, cell proliferation DNA methylation, DNA repair, and ion channel.

This array was used to evaluate gene expression in an arsenic-treated human cardiomyocyte cell line (AC16) and in blood from subjects living in Bayingorman (Ba Men) Inner Mongolia, China. This population has been exposed to a wide range of arsenic levels (from non-detectable to 1.8 mg/L), mainly via drinking water from contaminated artesian wells for more than 20 years \[[@b19-ijerph-08-02090]\]. Seafood consumption is not common in this population, and arsenic-containing pesticides have not been used in Ba Men \[[@b20-ijerph-08-02090]\]. In Ba Men, more than 300,000 people have been chronically exposed to arsenic, especially in three counties: Hangjin Hou, Lin He and Wu Yuan. Arsenic-associated health effects in this population include cancer, dermal, neurological, cardiovascular, and peripheral vascular diseases \[[@b9-ijerph-08-02090],[@b19-ijerph-08-02090]\]. More than 80 percent of the families owned individual wells, making it possible to assess the arsenic exposure at the individual level.

We assessed arsenic levels in the water from each household well and also in toenails and urine of each subject. This exposure assessment permitted us to associate gene expression in the blood of the subjects to each measure of exposure. In addition, we compared the results in the blood to those determined in cardiomyocytes exposed to arsenic *in vitro*. This provided an opportunity to see if arsenic might have a direct effect on such cells, resulting in changes in gene expression found in blood and/or consistent with the cardiovascular myopathies associated with arsenic exposure.

2.. Experimental Section
========================

2.1.. Study Subjects
--------------------

The study subjects included a total of 159 non-smoking Ba Men residents from the sub-villages of Wulan, Jianshe, Fengchan, and Xinyao located in Sha Hai Village, Hangjn Hou County and the sub-villages of Miaohao and Xigelian located in Sheng Feng Village, Wu Yuan County.

Questionnaires were administered to all participants to obtain demographic information, arsenic exposure, diet, smoking, occupation, pesticide use, and medical information. This study was conducted according to the recommendations of the World Medical Association Declaration of Helsinki \[[@b21-ijerph-08-02090]\] for international health research. All subjects gave written informed consent to participate in this study. The research protocol met the requirements for protection of human subject certification by the U.S. Environmental Protection Agency.

2.2.. Water Collection and Analysis
-----------------------------------

Samples of drinking water from wells were collected from all subjects' homes in acid-washed tubes, transported to the U.S. on blue ice, and analyzed for total arsenic using inductively coupled plasma mass spectrometry (ICPMS) as described previously \[[@b22-ijerph-08-02090]\]. The detection limit by ICPMS was 0.1 μg of As^III^/L.

2.3.. Toenail and Urine Collection and Analysis
-----------------------------------------------

Toenail samples were collected from the study subjects and analyzed as described previously \[[@b23-ijerph-08-02090]\]. The nail samples were first cleaned by sonication in HPLC-grade water, then acetone was added to remove the organic contaminants from the nail surface. Nail samples were analyzed for arsenic concentration by instrumental neutron activation analysis (INAA) at the Nuclear Services Department, North Carolina State University, Raleigh, NC, USA \[[@b24-ijerph-08-02090]\]. The detection limit by INAA was 0.012 μg of As^III^/g. Urine sample collection and analysis were the same as those described by \[[@b25-ijerph-08-02090]\]. Briefly, morning urine samples were collected from participants on three consecutive days and shipped on dry ice to the University of Alberta, Edmonton, AB, Canada for analysis. Inductively coupled mass spectrometry methods were used to measure urinary arsenic, with a detection limit of 0.5 μg of As^III^/L.

2.4.. Blood Collection, RNA Isolation, and cDNA Synthesis
---------------------------------------------------------

Blood samples were collected in PAXgene blood RNA tubes (Qiagen, Valencia, CA, USA) and then stored at −40 °C. The blood samples were transported to the U.S. A via air on blue ice and stored at −80 °C until RNA isolation. Total RNA was isolated using a PAXgene blood RNA kit according to the manufacturer's instructions. RNA was further subjected to DNase I treatment using the Turbo DNA-free Kit following manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). RNA quality was assessed by analysis with Agilent Bioanalyer 2100 Nono chip.

2.5.. cDNA Synthesis
--------------------

Total RNA was reverse-transcribed to cDNA by using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, CA, USA). The reaction mix was consisted of 2.5 U/μL of reverse transcriptase, 1.0 U/μL of RNase inhibitor, 0.4-mM dNTP, 0.2-μM random primers, and 2 μg RNA in 50 μL total volume. The reaction mixture was incubated at 25 °C for 10 min and then at 37 °C for 120 min. Finally, the mixture was heated at 85 °C for 5 s.

2.6.. TaqMan Low-Density Array
------------------------------

To identify altered gene expression in blood cells, we used a TLDA to examine the expression of 46 human genes. The 46 genes we selected occurred in several functional groupings ([Table 1](#t1-ijerph-08-02090){ref-type="table"}) that represented proposed mode-of-actions of arsenic based on human epidemiology, as well as animal and *in vitro* studies. For the present study, the TaqMan low-density array card was configured in to eight identical 48 genes set (duplicate per assay). Each set of genes contained two endogenous control genes, β-actin and 18s RNA. The cDNA (5 μL) was mixed with 45 μL of H~2~O and 50 μL of 2X TaqMan Universal PCR Mix (Applied Biosystems, Foster City, CA). Each sample (100 μL) was loaded into a port of the micro-fluid card and run on an ABI 7900HT System (ABI, CA) for 2 min at 50 °C, 10 min at 95 °C, followed by 40 cycles for 15 s at 97 °C and 1 min at 60 °C.

2.7.. *In Vitro* Studies
------------------------

The human cardiomyocyte cell line (AC16) was provided by one of us (M. Davidson) and were cultured in Dulbecco's Modified Eagle's/F12 medium supplemented with 12.5% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), penicillin (100 U/mL), and streptomycin (100 μg/mL) and maintained at 37 °C in 95% air and 5% CO~2~. The MTT cell-proliferation assay kit (Roche, Indianapolis, IN, USA) was used to assess cell viability. Briefly, 1X 10^4^ AC16 cells were seeded in 96-well plates in 0.2 mL of medium. After 24 h of incubation, sodium arsenite was added to the cultures at final concentrations of 0.1 to 5.0 μM, and cells were incubated for 3 days. Cell viability was measured at 560 nm and expressed as a percentage of controls. The assay was conducted in triplicate wells for each treatment, and a total of 3 experiments were conducted for all samples.

2.8.. Arsenite Treatment and RNA Isolation
------------------------------------------

After incubating the seeded cells for 24 h, the cells were treated with sodium arsenite (Sigma, St. Louis, MO, USA) at concentrations of 0 to 2.5 μM for 72 h. Total RNA was isolated from the control and the arsenite-treated cells using the RNeasy RNA Isolation Kit (Qiagen, CA, USA). cDNA synthesis and the TILDA were conducted as described above; each sample was tested in duplicate.

2.9.. Data Analysis
-------------------

The TLDA data were analyzed by SDS vers 2.2.2 software (ABI). Threshold cycle (Ct) data for all target genes and control gene 18s RNA were used to calculate ΔCt values \[ΔCt = Ct (target gene) -- Ct (18s RNA)\]. Then, ΔΔCt values were calculated by subtracting the calibrator (control) from the ΔCt values of each target. Multiple linear regression models were used to evaluate the relationship between gene expression (ΔCt) and nail, water, and urine arsenic levels. Because arsenic measures were highly right-skewed, they were log~10~-transformed prior to analysis. The dependent variable was gene expression as measured by ΔCt value, and the independent variable of interest was the log-transformed arsenic measure. Log transformation did not improve the skew of ΔCt measures, which tended to be fairly symmetric.

Three types of models were constructed: an unadjusted model; a model that included variables to adjust for age and sex; and a model adjusting for age, body mass index, sex, alcohol use, pesticide exposure in the past five years, and education level. Because adjusting for factors other than age and sex did little to change the relationship between arsenic density and gene expression, results adjusting for age and sex were reported. Slope coefficients shown in [Table 3](#t3-ijerph-08-02090){ref-type="table"} can be interpreted as the change in gene expression (ΔCt) associated with a 1-log~10~ increase in the water, urine, or nail arsenic levels. Non-linearity in the relationship between arsenic and gene expression was evaluated by fitting a two-degree fractional polynomial model and comparing it with a linear model using a deviance difference test \[[@b26-ijerph-08-02090]\]. Statistical analyses were conducted using Stata SE version 10.1 (Stata Corporation, College Station, TX, USA, 2008).

3.. Results
===========

3.1.. Study Subjects
--------------------

Demographic information and pesticide use related to the study subjects are shown in [Table 2](#t2-ijerph-08-02090){ref-type="table"}. All subjects were non-smokers. Most (79%) of the 159 study subjects, including 48 males and 111 females, were farmers. The nail arsenic concentrations ranged from 0.24 to 63.14 μg/g. Water arsenic concentrations ranged from non-detectable to 826 mg/L. The average years of arsenic exposure for the study subjects was 13 ± 6 (SD) years.

3.2.. Variability of Gene Expression Data from TLDA
---------------------------------------------------

To assess the reproducibility of the TILDA, sixteen samples of cDNAs from human blood were run repeatedly. ΔCt (The Ct values normalized to loading control) for experiment 1 were plotted against ΔCt for repeated TLDA experiments. The data showed a small variation with high correlation coefficients (0.985 and 0.971) ([Figures 1A,B](#f1-ijerph-08-02090){ref-type="fig"}). The data showed that the ΔCts were reproducible.

3.3.. Arsenic-Altered Gene Expression in the Blood
--------------------------------------------------

The TLDA showed that the majority of selected genes were expressed in the blood, most of them with Cts \< 30. However, *hTERT* and *CANC1* were under the detectable limit (Ct \> 37) and, thus, were excluded from further analysis. A linear regression was employed to determine the significance of association of expression with water arsenic levels. The data from *KCNA5* and *TNFα* expression showed a positive association with water arsenic exposure ([Table 3](#t3-ijerph-08-02090){ref-type="table"}). Furthermore, the expression level of KCNA5 was also associated with nail arsenic concentrations, whereas that of TNF-α was also associated with urine arsenic concentrations.

In addition to *KCNA5* and *TNF*-α, the altered expressions of nine other genes were associated with urinary arsenic concentrations ([Table 3](#t3-ijerph-08-02090){ref-type="table"}). The associated molecular functions for these 11 gene products included stress response, inflammation, apoptosis, DNA methylation, DNA repair, and the NF-κB signal transduction pathway. TNF-α is the prototypic pro-inflammatory cytokine and master regulator of cell apoptosis, inflammation, and tumorigenesis. TNF-α is an important constituent of the NF-kB signal pathway. There was no evidence of a significant (*p* \< 0.05) non-linear relationship between water, nail, or urine arsenic levels and gene expression, and in all cases a 2-degree fractional polynomial model was not an improvement over a linear regression model.

3.4.. Cardiomyocytes Treated with Arsenite *In Vitro*
-----------------------------------------------------

Results from the MTT assay showed that the viability of AC16 cells after arsenic treatment decreased as arsenite concentrations increased ([Figure 2](#f2-ijerph-08-02090){ref-type="fig"}). For the mRNA levels of 46 genes, three different patterns of response were observed. The expression of one group of genes was increased at low concentrations of arsenic (0.5 and 1 μM) but decreased at higher concentrations (\>2.5 μM, [Figure 3A](#f3-ijerph-08-02090){ref-type="fig"}). These included the genes associated with heat shock proteins, inflammatory molecules, apoptosis, DNA repair, and the NFkB pathways ([Figure 3A](#f3-ijerph-08-02090){ref-type="fig"}). A second group, including the genes *HMOX1*, *NQO1* and *ESR1*, showed increased expression relative to increased arsenic concentrations up to 5 μM ([Figure 3B](#f3-ijerph-08-02090){ref-type="fig"}). A third group showed down-regulated gene expression relative to arsenic concentration, and these included the ion channel genes *CACNA1C, KCNE1, KCNQ1* and *SCDA5*; the DNA repair genes *ERCC1* and *NTHL1*; and the cytokine gene IL6 ([Figure 3C](#f3-ijerph-08-02090){ref-type="fig"}).

Values in [Figure 3](#f3-ijerph-08-02090){ref-type="fig"} are fold changes of expression in treated cells relative to control cells. The ΔCt values of untreated cells were designated as calibrators. The relative quantity (RQ) was calculated by the equation RQ = 2^−ΔΔCt^. (A) Up-regulated gene expression at low concentrations of arsenic but down-regulated expression at high concentrations (2.5 μM). (B) Up-regulated gene expression relative to increasing concentrations of arsenic. (C) Down-regulated gene expression relative to increasing concentrations of arsenic.

4.. Discussion
==============

4.1.. Changes in Gene Expression in Blood Associated with Chronic Arsenic Exposure
----------------------------------------------------------------------------------

In this study, we investigated the molecular responses to arsenic exposure in humans and cultured cardiomyocytes using a novel TLDA in order to better understand the mode of action of arsenic. In blood, we found that alterations in expression of 11 genes, especially those associated with stress response, DNA repair, DNA methylation, the NF-κB signaling pathway, and iron channels, were positively associated with arsenic exposure. Urinary arsenic concentrations were associated with altered expression of 10 genes, 8 of which were associated only with urinary arsenic levels. Expression of 3 genes was associated with binary combinations of the 3 exposure assessments ([Table 3](#t3-ijerph-08-02090){ref-type="table"}). Based on the TLDA we designed, urinary arsenic was the most robust measure of exposure. Considering all the exposure estimates, expression of *TNF-α* was associated with both water and urinary concentrations of arsenic, that of *POLB* was associated with nail and urinary levels, and that of *KCNA5* was associated with water and nail levels (and was borderline significant with urinary arsenic). Because altered expression of these genes was associated with 2 of the 3 exposure assessments, we view that arsenic exposure clearly played a role in the altered expression of *KCNA5*, *TNF-α*, and *POLB* as assessed by the TLDA in this study.

Our finding that altered gene expression was associated most frequently with urinary arsenic levels is interesting in light of the finding that urinary arsenic levels were a stronger predictor of skin lesions than arsenic levels in drinking water \[[@b27-ijerph-08-02090],[@b28-ijerph-08-02090]\]. In addition, chromosomal aberrations have been shown to be associated with urinary arsenic \[[@b29-ijerph-08-02090]\]. Urinary arsenic receives input from external sources and tissue storage and likely reflects the body burden of arsenic. Consequently, altered gene expression associated with urinary arsenic may reflect current arsenic exposure levels.

Expression of *KCNA5* influences various cell functions, such as cell migration, proliferation and apoptosis. Over-expression of human *KCNA5* in pulmonary artery smooth muscle cells induced membrane hyperpolarization and increased cell apoptosis \[[@b30-ijerph-08-02090]\]. Down-regulation of *KCNA5* expression by an antisense oligonucleotide resulted in membrane depolarization \[[@b31-ijerph-08-02090]\]. *KCNA5* expression occurs in response to oxidative stress mediated by the Sp1 transcription factor \[[@b32-ijerph-08-02090]\].

TNF-α is a cytokine involved in cell proliferation, differentiation, and apoptosis. Induction of TNF-α by arsenic exposure has been observed consistently both *in vitro* and *in vivo* \[[@b33-ijerph-08-02090],[@b34-ijerph-08-02090]\]. Over-expression of *TNF-α* and *GM-CSF* has been associated with neoplastic transformation in the skin. *TGF*-α transgenic mice exhibited keratinocyte hyper-proliferation and tumors in the epithelium \[[@b35-ijerph-08-02090]\]. Our PCR array profiling showed that *TNF*-α expression was positively associated with chronic arsenic exposure, indicating that this inflammation cytokine is involved in arsenic toxicity and possibly carcinogenesis. Some TNFs may induce both apoptotic and anti-apoptotic pathways, the increased expression of TNF-α, along with BCL2 and BAX, strongly indicate the activation of the anti-apoptotic/NF-κB/BCL2 pathway in the subjects exposed to environmental arsenic.

Expression of *JUN* and *MAF* was positively associated with urinary arsenic levels in this study. The coordinated induction of these two genes suggests that the *Nrf2* pathway plays a crucial role in the cellular defense against arsenic-induced oxidative stress, which has been reported to be involved in the toxicity induced by low-dose arsenic exposure \[[@b36-ijerph-08-02090]\]. The Nrf2 pathway plays an important role by mediating an antioxidant response against the adverse effects of excess ROS production generated by arsenic metabolites \[[@b37-ijerph-08-02090]\]. The transcription factor Nrf2 is a central regulator in the activation of many genes related to antioxidant response, such as glutathione S-transferase (*GST*), *NAD(P)H*, quinine reductases (*NQO1*), heat shock protein, and heme oxygenase 1 (*HO-1*). Although we did not have *GGT1* or *NFKBIE* on our array, their expression levels in lymphoblasts may be biomarkers of susceptibility arsenic toxicity \[[@b38-ijerph-08-02090]\].

The small Maf basic leucine zipper protein has emerged as a crucial regulator of mammalian gene expression. During oxidative stress, Nrf2 heterodimerizes with small Maf and binds antioxidant response element (ARE) sequences, thereby transcriptionally activating ARE \[[@b37-ijerph-08-02090]\]. The activator protein (AP-1) transcription factor is a protein complex consisting c-Jun and c-Fos, which are involved in the regulation of many different kind of cellular processes, including proliferation and survival, differentiation, and transformation. Consistent with this is the finding that expression of *c-Jun* and *c-Fos* was up-regulated in human GM847 fibroblast cells exposed to arsenic \[[@b39-ijerph-08-02090]\]. Our finding of up-regulated expression of *c-Jun* and *Maf* in humans exposed chronically to arsenic suggests that arsenic may alter *AP-1* and *NF*-κ*b* activity. The NFκB signaling pathway is involved in the immune response, inflammation, and apoptosis, and the inflammation/NF-κB signaling pathway was reported to be activated in infants born to arsenic-exposed mothers \[[@b15-ijerph-08-02090]\]. Our data and that of others \[[@b15-ijerph-08-02090],[@b40-ijerph-08-02090]\] suggest that NFκB activation induced by arsenic exposure may play an important role in arsenic toxicity in humans.

Arsenic exposure is associated with a variety of diseases, including cancer, cardiovascular disease, and diabetes \[[@b1-ijerph-08-02090],[@b8-ijerph-08-02090],[@b41-ijerph-08-02090]\]. The mechanisms underlying the carcinogenicity of arsenic are varied; however, oxidative stress is a likely mode of action for arsenic \[[@b1-ijerph-08-02090],[@b3-ijerph-08-02090]\]. Arsenic metabolites generate ROS, resulting in damage to DNA and other macromolecules. For example, ROS-generating metabolites of arsenic can induce DNA breaks, resulting in chromosomal mutations \[[@b42-ijerph-08-02090]\]. The association of arsenic exposure with increased gene expression of nucleotide excision repair, DNA methylation, and oxidative DNA repair pathways observed in this study is consistent with this mechanism of arsenic carcinogenicity. As discussed below, oxidative stress may also play a role in the cardiovascular diseases associated with arsenic exposure, further supporting a role for the genes identified here in arsenic-associated disease.

4.2.. Changes in Gene Expression in Arsenic-Exposed Cardiomyocytes
------------------------------------------------------------------

Several reviews have concluded that arsenic exposure is associated with cardiovascular disease \[[@b8-ijerph-08-02090],[@b41-ijerph-08-02090],[@b43-ijerph-08-02090]\]. The specific diseases include carotid atherosclerosis, reduced microcirculation, prolonged QT interval and increased QT dispersion, hypertension, coronary artery disease, and cerebral infarction. Epidemiology studies support the view that chronic arsenic exposure is an independent risk factor for cardiovascular disease. Our previous work has demonstrated a clear relationship between chronic arsenic exposure and QT interval prolongation \[[@b5-ijerph-08-02090]\].

The mechanistic basis for this collection of arsenic-associated health effects appears to involve a role for oxidative stress and activated immune response pathways, indicating a pro-hyperinflammatory condition \[[@b8-ijerph-08-02090]\]. In arsenic-exposed mice, the arterial wall is inflamed, and liver sinusoidal endothelium differentiates into a continuous endothelium that limits nutrient exchange and waste elimination. Thus, current models focus on altered signaling by arsenic, resulting in inflammation of liver and heart arteries \[[@b8-ijerph-08-02090]\].

To our knowledge, our study is the first to expose heart cells (cardiomyocytes) to arsenic *in vitro*. We found that 25 of the 46 genes assessed by our TLDA exhibited altered expression after exposure of cardiomyocytes to arsenic ([Figure 3](#f3-ijerph-08-02090){ref-type="fig"}). Most interesting was that these affected genes fell into three categories: (1) those whose expression was up-regulated at low concentrations of arsenic but down-regulated at high concentrations of arsenic ([Figure 3A](#f3-ijerph-08-02090){ref-type="fig"}), those whose expression was up-regulated with increasing concentrations of arsenic ([Figure 3B](#f3-ijerph-08-02090){ref-type="fig"}), and those whose expression were down-regulated with increasing concentrations of arsenic ([Figure 3C](#f3-ijerph-08-02090){ref-type="fig"}).

Various studies have noted consistently that, for some genes, arsenic induces expression at low doses but reduces expression at high doses *in vitro* and *in vivo*. In human keratinocytes, sodium arsenite induced apurinic/apyrimidinic endonuclease, DNA polymerase β, DNA ligase, and telomerase up to 1 μM, but down-regulated these genes at concentration \>1 μM \[[@b39-ijerph-08-02090],[@b44-ijerph-08-02090],[@b45-ijerph-08-02090]\]. The sub-micromolar concentrations of sodium arsenite used in our study are similar to the levels of arsenic found in the blood of subjects exposed chronically to arsenic in Inner Mongolia \[[@b46-ijerph-08-02090]\]. These results suggest that low doses of arsenic trigger an adaptive response that alleviates the adverse effects of arsenic cytotoxicity and oxidative stress. Some of this response could protect against cancer by elevated DNA repair capacity. Other responses, such as increased cell proliferation, or inhibited apoptosis, may be cytoprotective, but could also be procarcinogenic by allowing mutant cells to survive.

Transcriptional regulation plays a key role in the regulation of potassium channel genes involved in cardiac muscle function and accounts for some of the variation of the elecrtro-physiological phenotype of myocytes \[[@b47-ijerph-08-02090]\]. Therefore, expression of *KCNA5* may have been altered by arsenic in the cardiomyocytes, but because of the low levels of this mRNA in our cells, we could not confirm such a change. However, we observed transcriptional changes for several iron-channel genes, including *KCNE1, KCNH2,* and *CADA1C* in cardiomyocytes treated with arsenite. Alterations in such genes could play a role in the cardiac arrhythmias associated with arsenic exposure \[[@b5-ijerph-08-02090],[@b48-ijerph-08-02090]\].

As noted earlier, epidemiological studies have identified arsenic exposure as a causative agent for diabetes \[[@b5-ijerph-08-02090],[@b41-ijerph-08-02090],[@b43-ijerph-08-02090]\]. Although we did not design our TLDA to assess genes potentially involved in arsenic-associated diabetes, recent studies \[[@b49-ijerph-08-02090],[@b50-ijerph-08-02090]\] suggest that the arsenic-associated decrease in insulin secretion found in rodent models may be partially responsible for the altered cell division and proliferation associated with arsenic exposure. *In vitro* studies found that free Ca^(2+)^ oscillations needed for glucose-stimulated insulin secretion were abated in the presence of subchronic, low arsenite concentrations \[[@b50-ijerph-08-02090]\]. Thus, it is interesting that we found that arsenic reduced expression of a variety of ion channel genes, including the calcium channel, voltage-dependent, L type alpha 1C subunit gene *CACNA1C* in cardiomyocytes ([Figure 3C](#f3-ijerph-08-02090){ref-type="fig"}). Although it is difficult to make firm conclusions and direct comparisons of gene expression in cardiomyocytes and blood due to the nature of the study design and differences in absorption and metabolismwe found that five genes showed altered expression both in blood and in the treated cardiomyocytes: *BAX, DNMT1, JUN, NTHL1,* and *RAD50*.

5.. Conclusions
===============

In conclusion, this study shows that the TLDA is a sensitive and reproducible technique for quantifying expression of multiple genes. Our finding in the blood of arsenic-exposed subjects of the simultaneous increase in gene expression involved in antioxidant response, inflammatory response, DNA repair, apoptosis, DNA methylation, and iron channels, suggests an integrative mode of action of arsenic in humans. Oxidative stress, inflammatory response, and altered ion-channel function may underlay aspects of the cancer, cardiovascular disease, and diabetes associated with chronic arsenic exposure. A recent study has also identified the importance of epigenetic changes in people with arsenicosis \[[@b51-ijerph-08-02090]\]. Further studies involving specific cell types are needed to identify the complete set of pathways affected by arsenic that result in the array of seemingly unrelated diseases.

We thank the staff members of the Inner Mongolia Center for Endemic Disease Control and Research and Ba Men Anti-epidemic Station who participated in this study. The research described here has been reviewed by the National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use.

![Viability of cardiomyocytes exposed to sodium arsenite. AC16 cells were seeded in a 96-well plate and exposed for three days to various concentrations of sodium arsenite. Cell viability was determined by the MTT assay. Data shown are mean ± SD from three independent experiments.](ijerph-08-02090f1){#f1-ijerph-08-02090}

![Correlation plot of mean ΔCt values from repeated TLDA experiments. Panels A and B show representative ΔCt values obtained from repeated experiment with two different samples. The ΔCt (The Ct values normalized to loading control) for experiment 1 was plotted against the ΔCt for repeated TILDA runs. Linear regression analysis was used to determined Pearson correlation coefficient (r) and *p* values.](ijerph-08-02090f2){#f2-ijerph-08-02090}
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Gene expression analysis of cardiomyocyte AC16 cells exposed to sodium arsenite for 72 h as determined by a TLDA.
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###### 

Genes analyzed by TLDA.

  **Gene symbol and assay ID**   **Functional group**   **Gene description**
  ------------------------------ ---------------------- ----------------------------------------------------------------------
  ACTB-Hs00242273_m1             Endogenous control     beta actin
  18S-Hs99999901_s1              18S Ribosomal RNA      
                                                        
  HMOX1-Hs00157965_m1            Nrf2 pathway           
  KEAP1-Hs00202227_m1                                   kelch-like ECH-associated protein 1
  MAF-Hs00193519_m1                                     
  MT1A-Hs00831826_s1                                    
  NQO1-Hs00168547_m1                                    
                                                        
  HSPA1A-Hs00359163_s1           Heat shock protein     
  HSP90AA1-Hs00743767_sH                                
                                                        
  BAX-Hs00180269_m1              Apoptosis              
  BCL2-Hs00153350_m1                                    
                                                        
  IL1B-Hs00174097_m1             Inflammation           
  IL2-Hs00174114_m1                                     
  IL6-Hs00174131_m1                                     
  TNF-Hs00174128_m1                                     
                                                        
  CHUK-Hs00175141_m1             NF-κB pathway          
  NFE2L2-Hs00232352_m1                                  nuclear factor (erythroid-derived 2)-like 2
  NFKB1-Hs00231653_m1                                   nuclear factor in B-cells 1 (p105)
  NFKB2-Hs00174517_m1                                   nuclear factor in B-cells 2 (p49/p100)
  RELB-Hs00232399_m1                                    
  RELA-Hs00153294_m1                                    
                                                        
  CDKN1A-Hs00355782_m1           Cell proliferation     
  CCND1-Hs00277039_m1                                   
  ESR1-Hs00174860_m1                                    
  FOS-Hs00170630_m1                                     
  JUN-Hs99999141_s1                                     
  MYC-Hs00153408_m1                                     
  MSH2-Hs00179887_m1                                    
  NRAS-Hs00180035_m1                                    
  TERT-Hs00162669_m1                                    
                                                        
  DNMT1-Hs00154749_m1            DNA methylation        DNA (cytosine-5-)-methyltransferase 1
  DNMT3A-Hs00173377_m1                                  
                                                        
  ERCC1-Hs00157415_m1            DNA repair             
  MGMT-Hs00172470_m1                                    
  NTHL1-Hs00267385_m1                                   
  OGG1-Hs00213454_m1                                    
  POLB-Hs00160263_m1                                    
                                                        
  DNMT1-Hs00154749_m1            DNA methylation        DNA (cytosine-5-)-methyltransferase 1
  RAD50-Hs00194871_m1                                   
  TP53-Hs00153349_m1                                    
                                                        
  CACNA1C-Hs00167681_m1          Ion channel            calcium channel, voltage-dependent, L type, alpha 1C subunit
  SCN5A-Hs00165693_m1                                   sodium channel, voltage-gated, type V, alpha (long QT syndrome 3)
  KCNJ2-Hs00265315_m1                                   potassium inwardly-rectifying channel, subfamily J, member 2
  KCNA5-Hs00266898_s1                                   potassium voltage-gated channel, shaker-related subfamily, member 5
  KCND3-Hs00542597_m1                                   potassium voltage-gated channel, Shal-related subfamily, member 3
  KCNE1-Hs00264799_s1                                   potassium voltage-gated channel, Isk-related family, member 1
  KCNQ1-Hs00165003_m1                                   potassium voltage-gated channel, KQT-like subfamily, member 1
  KCNH2-Hs00165120_m1                                   potassium voltage-gated channel, subfamily H (eag-related), member 2
  KCNE2-Hs00270822_s1                                   potassium voltage-gated channel, Isk-related family, member 2

###### 

Selected characteristics of study population.

  **Variables**                         **Number of subjects**   **Percent**
  ------------------------------------- ------------------------ -------------
  *Gender*                                                       
    Male                                48                       30.2
    Female                              111                      69.8
  *Age*                                                          
    11--18                              49                       30.8
    19--49                              93                       58.5
    \>50                                17                       10.7
  *Occupation*                                                   
    Farmer                              110                      69.6
    Other                               48                       30.4
  *Education*                                                    
    None                                24                       15.2
    Elementary                          50                       31.6
    Jr high school                      76                       48.1
    High school                         8                        5.1
  *Meat frequency*                                               
    Often                               159                      100
  *Vegetable frequency*                                          
    Occasionally                        1                        0.6
    Often                               158                      99.4
  *Use of pesticides in past 5 years*                            
    Yes                                 45                       28.3
    No                                  114                      71.7
  *Alcohol use 2 x/week*                                         
    No                                  114                      95.6
    Yes                                 7                        4.4
  *Eat fish frequency*                                           
    Never                               1                        0.6
    Occasionally                        146                      91.8
    Often                               12                       7.5

###### 

Association of gene expression with water, nail, or urine arsenic levels[^a^](#tfn1-ijerph-08-02090){ref-type="table-fn"}.

  **Gene**   **Function group**    **Water arsenic**   **Nail arsenic**   **Urine arsenic**                   
  ---------- --------------------- ------------------- ------------------ ------------------- ------- ------- -------
  *KCNA5*    Ion channel           0.343               0.031              0.547               0.043   0.189   0.078
  *TNF-α*    Inflammation          0.178               0.043                                          0.146   0.013
  *POLB*     DNA repair                                                   0.306               0.049   0.135   0.028
  *MAF*      Nrf2 pathway                                                                             0.137   0.038
  *BCL2*     Apoptosis                                                                                0.131   0.033
  *BAX*      Apoptosis                                                                                0.117   0.038
  *DNMT1*    DNA methylation                                                                          0.122   0.031
  *HSP1*     Heat shock protein                                                                       0.105   0.054
  *JUN*      Signal transduction                                                                      0.149   0.023
  *NTHL1*    DNA repair                                                                               0.132   0.034
  *RAD50*    DNA repair                                                                               0.113   0.050

Only those slopes and *p*-values with significant association with arsenic (*p* \< 0.05) are shown;

N = 159, *p*-values were age and sex adjusted.
